AAUM (Average Assets Under Management) of ₹538.60 Cr for Apr-Jun 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 72.7% | 72.1% | ▼ -0.5% |
| Healthcare Services | 17.2% | 19.7% | ▲ +2.5% |
| Insurance | 5.4% | 2.3% | ▼ -3.2% |
| IT - Services | 1.5% | 1.4% | ▼ -0.1% |
| Retailing | 1.2% | 1.1% | ● -0.1% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 72.1% | 74.6% | ▲ +2.5% |
| Healthcare Services | 19.7% | 19.5% | ▼ -0.2% |
| Insurance | 2.3% | 2.9% | ▲ +0.6% |
| Retailing | 1.1% | 0.9% | ▼ -0.2% |
| IT - Services | 1.4% | 0.9% | ▼ -0.6% |
Comparing Jul 2026 → Aug 2026
| # | Stock | Sector | Weight (Aug 2026) |
|---|---|---|---|
| 1 | Symbiotec Pharmalab Limited ₹6.00 Cr |
Pharmaceuticals & Biotechnology | 1.18% |
| 2 | GlaxoSmithKline Pharmaceuticals Limited ₹3.66 Cr |
Pharmaceuticals & Biotechnology | 0.72% |
| 3 | Life Insurance Corporation Of India ₹2.41 Cr |
Insurance | 0.48% |
| # | Stock | Sector | Jul 2026 | Aug 2026 | Change |
|---|---|---|---|---|---|
| 1 | Divi's Laboratories Limited ₹40.64 Cr |
Pharmaceuticals & Biotechnology | 6.66% | 8.01% | +1.35% |
| 2 | IPCA Laboratories Limited ₹31.60 Cr |
Pharmaceuticals & Biotechnology | 5.72% | 6.23% | +0.51% |
| 3 | Laurus Labs Limited ₹28.73 Cr |
Pharmaceuticals & Biotechnology | 5.24% | 5.66% | +0.42% |
| 4 | Manipal Health Enterprises Ltd ₹6.46 Cr |
Healthcare Services | 0.96% | 1.27% | +0.31% |
| 5 | Sun Pharmaceutical Industries Limited ₹45.70 Cr |
Pharmaceuticals & Biotechnology | 8.82% | 9.01% | +0.19% |
| 6 | Max Financial Services Limited ₹12.35 Cr |
Insurance | 2.27% | 2.43% | +0.16% |
| 7 | Dr. Lal Path Labs Limited ₹16.44 Cr |
Healthcare Services | 3.12% | 3.24% | +0.12% |
| 8 | Apollo Hospitals Enterprise Limited ₹27.59 Cr |
Healthcare Services | 5.35% | 5.44% | +0.09% |
| 9 | Acutaas Chemicals Ltd ₹11.39 Cr |
Pharmaceuticals & Biotechnology | 2.15% | 2.24% | +0.09% |
| 10 | Concord Biotech Limited ₹10.85 Cr |
Pharmaceuticals & Biotechnology | 2.05% | 2.14% | +0.09% |
| # | Stock | Sector | Jul 2026 | Aug 2026 | Change |
|---|---|---|---|---|---|
| 1 | Torrent Pharmaceuticals Limited ₹40.53 Cr |
Pharmaceuticals & Biotechnology | 8.58% | 7.99% | -0.59% |
| 2 | Inventurus Knowledge Solutions Limited ₹4.34 Cr |
IT - Services | 1.42% | 0.85% | -0.57% |
| 3 | AstraZeneca Pharma India Limited ₹18.07 Cr |
Pharmaceuticals & Biotechnology | 4.05% | 3.56% | -0.49% |
| 4 | Lupin Limited ₹30.42 Cr |
Pharmaceuticals & Biotechnology | 6.46% | 5.99% | -0.47% |
| 5 | Nephrocare Health Services Ltd ₹6.83 Cr |
Healthcare Services | 1.74% | 1.35% | -0.39% |
| 6 | Zydus Lifesciences Limited ₹10.92 Cr |
Pharmaceuticals & Biotechnology | 2.47% | 2.15% | -0.32% |
| 7 | Aster DM Healthcare Limited ₹11.34 Cr |
Healthcare Services | 2.53% | 2.23% | -0.30% |
| 8 | MedPlus Health Services Limited ₹4.71 Cr |
Retailing | 1.09% | 0.93% | -0.16% |
| 9 | Abbott India Limited ₹11.63 Cr |
Pharmaceuticals & Biotechnology | 2.41% | 2.29% | -0.12% |
| 10 | Emcure Pharmaceuticals Limited ₹12.08 Cr |
Pharmaceuticals & Biotechnology | 2.46% | 2.38% | -0.08% |
33 stocks — Aug 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹45.70 Cr |
Pharmaceuticals & Biotechnology |
9.01%
|
|
| 2 |
₹40.64 Cr |
Pharmaceuticals & Biotechnology |
8.01%
|
|
| 3 |
₹40.53 Cr |
Pharmaceuticals & Biotechnology |
7.99%
|
|
| 4 |
₹31.60 Cr |
Pharmaceuticals & Biotechnology |
6.23%
|
|
| 5 |
₹30.42 Cr |
Pharmaceuticals & Biotechnology |
5.99%
|
|
| 6 |
₹28.73 Cr |
Pharmaceuticals & Biotechnology |
5.66%
|
|
| 7 |
₹27.59 Cr |
Healthcare Services |
5.44%
|
|
| 8 |
₹22.85 Cr |
Healthcare Services |
4.50%
|
|
| 9 |
₹18.07 Cr |
Pharmaceuticals & Biotechnology |
3.56%
|
|
| 10 |
₹17.36 Cr |
Pharmaceuticals & Biotechnology |
3.42%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.